Manuel Gonzales Iv

Manuel Gonzales Iv

Auto-generated profile, based on publicly available information

Manuel Gonzales Iv

SDSU/UCSD Joint Doctoral Program in Clinical Psychology, 5500 Campanile Drive, San Diego, CA, 92182, United States, 1 619-594-1919

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2021 in International Journal of Eating Disorders
Verified
Journal Article
Closed access
PDF file
PKPatrycja Klimek
Patrycja Klimek
ACAlexandra D. Convertino
Alexandra D. Convertino
JPJamie‐Lee Pennesi
Jamie‐Lee Pennesi
MGManuel Gonzales
Manuel Gonzales
SRScott C. Roesch
Scott C. Roesch
ABAaron J. Blashill
Aaron J. Blashill

2 December 2025 in Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies
Verified
Journal Article
Open access
FYFangxu Yuan
Fangxu Yuan
NKNavreet Kaur
Navreet Kaur
ZWZhiyuan Wang
Zhiyuan Wang
MIManuel Gonzales Iv
Manuel Gonzales Iv
CACristian Garcia Alcaraz
Cristian Garcia Alcaraz
LBLaura Barnes
Laura Barnes
Many breast cancer survivors are prescribed daily oral medications called endocrine therapy that prevent cancer recurrence. Despite its clinical importance, maintaining consistent daily adherence remains challenging due to the dynamic and interrelated influences of behavioral, physiological, and psychological factors. While prior studies have explored adherence prediction using mobile sensing, they often rely on single-modality data, limited temporal granularity, or aggregate-level modeling—limiting their ability to capture short and long-term behavioral variability and to facilitate deeper understanding of non-adherence and tailored interventions. To address these gaps, we propose a multimodal sensing framework that explicitly models daily adherence dynamics using temporally adaptive inputs. We recruited a sample of breast cancer survivors ( N = 20) and collected longitudinal data streams including wearable-derived physiological features (Fitbit), medication event monitoring system (MEMS) data, and ecological momentary assessments (EMAs). Using multimodal data across varying time windows, we examined whether recent patterns in behavioral, physiological, psychological, and environmental factors improve the prediction of next-day endocrine therapy adherence. Our results demonstrate the feasibility of using multimodal sensing data to predict daily adherence with moderate accuracy. Moreover, models integrating multimodal data consistently outperformed those relying on a single modality. Importantly, we observed that the predictive value of each modality varied depending on the temporal proximity of the input signals, underscoring the importance of modeling immediate and longer-term behavioral patterns. The findings offer valuable insights for advancing adherence monitoring systems, suggesting that incorporating personalized and temporally adaptive data fusion strategies may significantly enhance the effectiveness of intervention design and delivery.

30 April 2026 in JMIR Cancer
Verified
Journal Article
Open access
MIManuel Gonzales Iv
Manuel Gonzales Iv
CACristian Garcia Alcaraz
Cristian Garcia Alcaraz
NKNavreet Kaur
Navreet Kaur
ABAnna N Baglione
Anna N Baglione
SLSarah Livermon
Sarah Livermon
KWKristen Wells
Kristen Wells
Background: Breast cancer is a significant public health burden. Despite its critical role in preventing the recurrence of breast cancer, rates of long-term adherence to endocrine therapy (ET) remain low among certain breast cancer survivors. Using embedded sensors in smartphones and wearables, ecological momentary assessment data and health behavior theory may facilitate a richer understanding of the real-world context of medication-taking behaviors, which can aid in the development of personalized interventions. Objective: The objective of this paper is to describe the development of a multiscale modeling intervention (MMI) system to facilitate adherence to daily oral ET for breast cancer survivors. This represents the first phase of a larger project that aims to use machine learning to predict when breast cancer survivors are most likely to miss their ET medications in order to deploy personalized interventions. The purpose of this paper was (1) to determine the acceptability of the proposed MMI system, (2) to identify modifiable predictors of ET medication adherence among breast cancer survivors, and (3) to select surveys or items measuring constructs associated with ET adherence among breast cancer survivors for inclusion in the MMI system. Methods: Study 1 consisted of usability interviews with a cohort of breast cancer survivors (n=25) prescribed ET. For study 1, all qualitative usability interviews were conducted using a semistructured interview guide and assessed whether breast cancer survivors were willing to use various components of the MMI system. Study 2 consisted of (1) a secondary data analysis of ET adherence data from 32 breast cancer survivors using a social cognitive theory framework and (2) a review of research literature of constructs and surveys measuring constructs associated with ET adherence among breast cancer survivors using a social cognitive theory framework. The secondary data analysis included the use of randomized neural network analysis to predict factors strongly associated with medication adherence. Results: In study 1, usability interview findings suggested that participants were willing to use an ecological momentary assessment smartphone app, a smartwatch and associated smartphone app, a smart pill bottle or smart pill box and associated smartphone app, and the entire MMI system for a 6-month study period. In study 2, the randomized neural network analysis identified 104 survey items with significant contributions to 4-week medication adherence using a threshold of the 70th percentile for feature importance. After a review of peer-reviewed studies, we abstracted modifiable constructs significantly associated with adherence to adjuvant ET and identified 42 surveys used to measure these constructs. When these findings were combined, the final survey for the MMI system consisted of 32 surveys and demographic items. Conclusions: Our research highlights the use of social cognitive theory, data-driven models, and participant feedback to inform the development of a medication adherence monitoring system. Data from studies 1 and 2 were used to develop a prototype MMI system that will be deployed in a future longitudinal study with 20 breast cancer survivors over 6 months.